Pharmaceutical centralized procurement work "focus"
At the end of 2023, the cumulative number of drugs collected in each province reached 450, each province to carry out at least one batch of provincial procurement of consumables, and deepen the pilot reform of the price of medical services ...... national health insurance The Bureau issued the "Notice on Doing a Good Job of Pharmaceutical Centralized Purchasing and Price Management in 2023" on the 1st, setting out the priorities for the pharmaceutical centralized purchasing work in 2023.
By the end of 2023, the cumulative number of medicines collected in each province will reach 450
The notice makes it clear that it will continue to expand the coverage of the centralized procurement of medicines, and that by the end of 2023, the cumulative number of medicines collected at the national and provincial levels in each province will reach 450, of which the provincial-level collection of medicines should reach 130, with coverage of chemical medicines, proprietary Chinese medicines, and biologically based medicines.
Till now, the state has organized 294 kinds of drugs collection and procurement, a number of hypertension, coronary heart disease, diabetes and other outpatient common diseases, chronic diseases, the average price reduction of more than 50%. Thanks to the significant price reductions, the proportion of patients using high-quality medicines has risen from 50 percent before the collection to more than 90 percent.
A few days ago, the Office of Joint Purchasing of Medicines by State Organizations issued the Notice on the Filling of Information on the Eighth Batch of Medicines Related to the Centralized Purchasing of Medicines by State Organizations, officially launching the filling of information on the eighth batch of related medicines, which involves about 40 kinds of medicines covering anti-infective, cardio-cerebral and cerebral vascular treatments and other fields.
In the standardization of the state organization of the centralized procurement of drugs agreement expires in succession, the notice is clear that the last round of the centralized procurement of the high price of varieties to continue to squeeze the price of water, the market situation changes after the last round of the centralized procurement of the low price of varieties, after full competition to form a new selected price.
In addition, the notice clearly will focus on guiding Hubei to take the lead in expanding the inter-provincial alliance purchasing varieties and regional scope of proprietary Chinese medicines, Jiangxi to take the lead in interferon inter-provincial alliance purchasing, Guangdong to take the lead in the inter-provincial alliance purchasing of easy shortages and emergency rescue medicines.
Continuing to carry out a new batch of state-organized high-value medical consumables procurement
In September 2022, the third batch of state-organized high-value medical consumables procurement focused on orthopaedic spinal consumables, and the proposed winning products reduced the price by an average of 84%.
The notice made it clear that we should do a good job of spinal consumables collection of selected results on the ground to implement, with reference to the practice of special adjustment of the price of artificial joint replacement surgery, prioritize the adjustment of the price of surgery related to the collection of spinal consumables.
In addition, will focus on cardiology, orthopedics key products, guide more provinces to promote anastomoses, ultrasonic knives and other general surgery consumables collection, continue to explore the in vitro diagnostic reagents collection, each province at least 1 batch of provincial level consumables collection. It will focus on guiding Shaanxi to take the lead in inter-provincial alliance procurement of dural (spinal) patch and hernia repair consumables, Henan to take the lead in inter-provincial alliance procurement of neurosurgery and other consumables, and Anhui to take the lead in inter-provincial alliance procurement of in vitro diagnostic reagents.
In January 2023, the oral implant system collection and procurement in Sichuan opened, the average winning price of the products to be selected to fall to more than 900 yuan, nearly 18,000 medical institutions to participate in the collection and procurement demand amounted to 2.87 million sets.
In the continued development of oral implant price special governance, the notice is clear to land the implementation of the implant system set mining results, to guide the medical institutions to prioritize the procurement and use of selected products. Sichuan Medical Insurance Bureau to take the lead in carrying out dental crowns competitive listing, other provinces timely follow-up linkage of Sichuan's dental crowns listing price. Provinces in mid-April before the full implementation of the full process of regulating the target.
Strengthening the supply guarantee of selected products Promoting the reform of medical service prices
The supply guarantee of medicines and consumables after the price reduction of collective purchasing has been a hotspot of public concern.
In this regard, the notice makes it clear that we should strengthen the supply guarantee of the selected products, establish an effective feedback mechanism for the supply guarantee of the collected varieties among the medical institutions, production and distribution enterprises, and pharmaceutical centralized purchasing agencies, enhance the sensitivity to deal with the supply and distribution problems, and take timely measures such as increasing the supply of deployment, replacement supply, and so on, and fail to supply the enterprises according to the requirements of the circumstances to give the appropriate level of credit evaluation.
In promoting the reform and management of medical service prices, the notice made it clear that Tangshan, Suzhou, Xiamen, Ganzhou, Leshan five national pilot cities to monitor the first round of price adjustment operation, and continue to improve the price formation mechanism.
At the same time, to strengthen the price management of listed drugs. Notice clear requirements to do a good job in the new version of the catalog of negotiated drugs and bidding drugs on the network, and strengthen the daily monitoring and dynamic management. Standardize the listing of drugs, withdrawal of network work, strictly prevent the change of drug listing license holder or change the specifications and packaging, such as "change the face" of the price increase behavior.
In addition, the notice makes it clear that the abnormal price increase, the overall high price or significantly higher than the national low price of the situation, the provinces should be timely to carry out letters of inquiry about reminders to correct improper price behavior.